Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

This summary is generated by an algorithm. If you find any mistakes, let us know.

Founded last year, Mozart Therapeutics lands $55M to develop therapies for celiac and other diseases
Founded last year, Mozart Therapeutics lands $55M to develop therapies for celiac and other diseases
UN

Unicorn Nest news

Founded last year, Mozart Therapeutics lands $55M to develop therapies for celiac and other diseases

- Mozart Therapeutics, a Seattle-based biotech startup, raised $55m funding. - The round was led by ARCH Venture Partners along with Sofinnova Partners. - Other backers include MRL Ventures Fund from Merck, Leaps by Bayer, and Eli Lilly & Company.

Source
GenEdit Announces Series A Financing and Provides Research Update at TIDES 2021
GenEdit Announces Series A Financing and Provides Research Update at TIDES 2021
UN

Unicorn Nest news

GenEdit Announces Series A Financing and Provides Research Update at TIDES 2021

– GenEdit has closed a $26m Series A financing.
– New investors include Eli Lilly, KTB Network, Company K Partners, Korea Investment Partners, DAYLI Partners, KB Investment, IMM Investment, and TIMEFOLIO Asset Management.
– The funding will support the further development of GenEdit’s NanoGalaxy™ platform of non-viral, non-lipid polymer nanoparticles, and the selection for clinical development of therapeutic candidates targeting diseases of the nervous system.

Source
Iterative Scopes Raises $30 Million Series A Financing to Advance AI-Driven Precision Medicine for Gastroenterology
Iterative Scopes Raises $30 Million Series A Financing to Advance AI-Driven Precision Medicine for Gastroenterology
UN

Unicorn Nest news

Iterative Scopes Raises $30 Million Series A Financing to Advance AI-Driven Precision Medicine for Gastroenterology

– Iterative Scopes closed a $30m Series A financing.
– The round was led by new investor Obvious Ventures, with participation from Eli Lilly, Johnson & Johnson Innovation, the venture capital firms Breyer Capital and Seae Ventures, as well as a number of leaders in healthcare, including Lee Shapiro, Zach Weinberg and Nat Turner.
– The funds will be used to further develop the company’s core algorithmic innovations and to advance its growing life sciences businesses.
– The company is building a powerful set of proprietary artificial intelligence (AI)-driven computational tools to identify appropriate treatments and guide clinical trials for patients suffering from gastrointestinal diseases.

Source
TRexBio Closes the Final Tranche of $59 Million Series A Financing to Advance Innovation in Tissue Immunobiology for the treatment of Cancer and Inflammatory Diseases
TRexBio Closes the Final Tranche of $59 Million Series A Financing to Advance Innovation in Tissue Immunobiology for the treatment of Cancer and Inflammatory Diseases
UN

Unicorn Nest news

TRexBio Closes the Final Tranche of $59 Million Series A Financing to Advance Innovation in Tissue Immunobiology for the treatment of Cancer and Inflammatory Diseases

– TRexBio, a discovery stage company decoding human tissue immune biology to create revolutionary therapeutics, announced the successful close of the final tranche of a $59m Series A financing.
– Proceeds from the financing will be used to expand the company’s unique discovery platform that maps human tissue regulatory T cell (Treg) behavior to dysregulation in disease, and to advance its six preclinical therapeutic programs.
– Investors include Eli Lilly and Company, SV Health, Johnson & Johnson Innovation, Pfizer Ventures, and Alexandria Venture Investments.
– TRexBio also announced the appointment of Johnston Erwin as Chief Executive Officer, and Ovid Trifan, M.D., Ph.D., as Chief Medical Officer, as part of the company’s plan to accelerate growth.

Source
Jaguar Gene Therapy Closes $139 Million Series B Funding Co-led by Eli Lilly and Company and Deerfield Management
Jaguar Gene Therapy Closes $139 Million Series B Funding Co-led by Eli Lilly and Company and Deerfield Management
UN

Unicorn Nest news

Jaguar Gene Therapy Closes $139 Million Series B Funding Co-led by Eli Lilly and Company and Deerfield Management

– Jaguar Gene Therapy announced a $139m Series B funding co-led by Eli Lilly and Company and Deerfield Management.
– Also participating in the round were ARCH Venture Partners, Goldman Sachs, and Nolan Capital.
– The company is advancing AXV101, a gene therapy treatment for BBS1, a subset of Bardet-Biedl syndrome (BBS). A life-threatening neurometabolic condition, BBS causes progressive vision loss, severe obesity, learning disorders and kidney disease.
– The company is leveraging a proven management team with the expertise to accelerate the development, manufacturing and commercialization of novel gene therapy treatments for patients suffering from severe genetic diseases.
– Jaguar is led by former AveXis leadership.

Source
Amphista Therapeutics Raises $53M in Series B Funding
Amphista Therapeutics Raises $53M in Series B Funding
UN

Unicorn Nest news

Amphista Therapeutics Raises $53M in Series B Funding

– Amphista Therapeutics from Glasgow, Scotland, UK, raised $53m in Series B funding.
– The round was co-led by Forbion and Gilde Healthcare with participation from Novartis Venture Fund, and Eli Lilly and Company, and existing investor BioMotiv and founding investor Advent Life Sciences.
– The new investment will be used to accelerate the company’s pipeline of potent and selective bifunctional molecules, known as ‘Amphistas’ to the clinic and to extend its proprietary TPD platform.

Source
Seraxis Announced Closing of $40M Series C Financing Round
Seraxis Announced Closing of $40M Series C Financing Round
UN

Unicorn Nest news

Seraxis Announced Closing of $40M Series C Financing Round

– Seraxis announced the closing of a $40M Series C financing round.
– The round was led by Eli Lilly and Company with participation from Frazier Healthcare Partners, Polaris Ventures, JDRF T1D Fund, and other investors.
– Seraxis is a privately held biotechnology company with operations located in the BioHealth Capital Region, Maryland.
– Seraxis proprietary transplant ready islets and device were developed in house.
– Seraxis is advancing its cell therapy/device combination, SR-01 to the clinic.

Source
1 2 3 58 59 60
Crunchbase icon

Content report

The following text will be sent to our editors: